8-K: Xilio Therapeutics Completes $25 Million Gilead Investment, Announces Promising Clinical Data and Upcoming Presentations

Xilio Therapeutics completed a $25 million private placement with Gilead, announced positive preliminary Phase 1 data for XTX301, and plans to present Phase 2 data for vilastobart at ASCO GI in January 2025.

Summary

• Xilio Therapeutics has completed a $25 million private placement with Gilead Sciences, fulfilling the maximum investment under their stock purchase agreement.
• The company received approximately $8.2 million in gross proceeds from the sale of common stock and prefunded warrants on December 18, 2024.
• Xilio's cash runway is now extended into the third quarter of 2025, based on current operating plans.
• Preliminary Phase 1 data for XTX301, a tumor-activated IL-12, shows sustained interferon gamma signaling without tachyphylaxis.
• XTX301 has demonstrated a favorable tolerability profile with no dose-limiting toxicities reported to date.
• Xilio plans to present initial Phase 2 data for vilastobart in combination with atezolizumab in MSS CRC at the ASCO GI Cancers Symposium in January 2025.
• The Phase 2 data presentation will include results from approximately 20 patients with MSS CRC.
• Additional Phase 2 data from approximately 40 patients is expected to be reported in mid-2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the completion of the Gilead investment, promising clinical data for XTX301, and upcoming Phase 2 data presentation for vilastobart. The company's financial position is strengthened, and there are no significant negative aspects mentioned.

Positives

• The completion of the $25 million private placement with Gilead strengthens Xilio's financial position.
• The extended cash runway into Q3 2025 provides financial stability for ongoing research and development.
• XTX301's preliminary Phase 1 data shows a promising tolerability profile and sustained interferon gamma signaling.
• The planned presentation of Phase 2 data for vilastobart at ASCO GI in January 2025 is a significant milestone.
• The company has observed a confirmed partial response in a MSS CRC patient with complete resolution of liver metastasis in the Phase 1 trial of vilastobart and atezolizumab.
• The tumor-activated design of XTX301 has shown no measurable activated XTX301 in peripheral circulation.

Negatives

• The document does not explicitly mention any negative aspects of the company's performance or results.
• The company is still in the clinical trial phase, and there is no guarantee of future success.

Risks

• The company's future success depends on the outcome of ongoing clinical trials.
• There are risks associated with the development and regulatory approval of new therapies.
• The company's financial position is dependent on continued funding and partnerships.
• General market conditions and international trade policies could impact the company's business.
• The company's ability to maintain its clinical trial collaboration with Roche and its license agreement with Gilead are critical to its success.

Future Outlook

Xilio anticipates that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2025. The company plans to present initial Phase 2 data for vilastobart at ASCO GI in January 2025 and additional Phase 2 data in mid-2025.

Management Comments

• Katarina Luptakova, M.D., chief medical officer of Xilio, stated that they are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation.
• Katarina Luptakova, M.D., also noted that the preliminary Phase 1 data for XTX301 highlights its promising clinical profile, including no dose-limiting toxicities and consistent interferon gamma signaling.

Industry Context

The announcement is relevant to the immuno-oncology field, particularly in the development of tumor-activated therapies. The focus on MSS CRC, a difficult-to-treat cancer, and the use of IL-12 and CTLA-4 inhibitors are key areas of interest in the industry. The collaboration with Roche and Gilead highlights the importance of partnerships in advancing novel therapies.

Comparison to Industry Standards

• The development of tumor-activated therapies is a growing trend in immuno-oncology, with companies like BioNTech and Moderna also exploring similar approaches.
• The use of IL-12 as a therapeutic agent has been challenging due to tolerability issues, and Xilio's XTX301 aims to address this limitation with its tumor-activated design, which is similar to approaches taken by companies like Bristol Myers Squibb with their cytokine programs.
• The combination of CTLA-4 and PD-1/PD-L1 inhibitors is a common strategy in immuno-oncology, with companies like Merck and Bristol Myers Squibb having approved therapies in this space. Xilio's vilastobart is designed to improve the efficacy and safety of CTLA-4 inhibition.
• The Phase 1 data for XTX301 showing no dose-limiting toxicities is a positive sign compared to historical data for recombinant human IL-12, which has been limited by poor tolerability. This is a key differentiator for Xilio's approach.
• The confirmed partial response in a MSS CRC patient with complete resolution of liver metastasis in the Phase 1 trial of vilastobart and atezolizumab is a promising result, as MSS CRC is known to be resistant to many immunotherapies. This result is comparable to early results seen in other novel immuno-oncology approaches.

Related Party Transactions

• The document details the private placement of stock and warrants to Gilead Sciences, Inc., a related party due to the licensing agreement.

Stakeholder Impact

• Shareholders will likely view the completion of the Gilead investment and the positive clinical data as favorable.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with cancer may benefit from the development of new therapies.
• The collaboration with Roche and Gilead could lead to further partnerships and opportunities.

Next Steps

• Xilio will present initial Phase 2 data for vilastobart in combination with atezolizumab at the ASCO GI Cancers Symposium in January 2025.
• The company will continue to enroll patients in Phase 1A monotherapy dose escalation and Phase 1B monotherapy dose expansion of its ongoing Phase 1 clinical trial of XTX301.
• Xilio plans to report additional Phase 2 data for vilastobart in mid-2025.

Key Dates

Keywords

Xilio Therapeutics, Gilead Sciences, XTX101, vilastobart, XTX301, IL-12, atezolizumab, immuno-oncology, clinical trials, MSS CRC, tumor-activated, private placement, ASCO GI